NASDAQ: DCPHDeciphera Pharmaceuticals Inc Stock
$25.46+0.01 (+0.04%)
Updated May 17, 2024
DCPH Price
$25.46
Fair Value Price
N/A
Market Cap
$2.20B
52 Week Low
$9.90
52 Week High
$25.55
P/E
-11.52x
P/B
6.97x
P/S
7.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$174.91M
Earnings
-$190.42M
Gross Margin
97%
Operating Margin
-108.62%
Profit Margin
-108.9%
Debt to Equity
0.33
Operating Cash Flow
-$152M
Beta
1.2
Next Earnings
Jun 20, 2024
Ex-Dividend
N/A
Next Dividend
N/A
DCPH Overview
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DCPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DCPH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DCPH is poor value based on its book value relative to its share price (6.97x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.2x)
P/B vs Industry Valuation
DCPH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DCPH due diligence checks available for Premium users.
Be the first to know about important DCPH news, forecast changes, insider trades & much more!
DCPH News
Valuation
DCPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-11.52x
Industry
-1.01x
Market
30.97x
DCPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.97x
Industry
2.2x
DCPH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DCPH's financial health
Profit margin
Revenue
$45.0M
Net Income
-$45.1M
Profit Margin
-100.2%
DCPH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
DCPH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$420.9M
Liabilities
$104.9M
Debt to equity
0.33
DCPH's short-term assets ($349.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DCPH's short-term assets ($349.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DCPH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DCPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$54.6M
Investing
$62.6M
Financing
$522.0k
DCPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DCPH vs Pharmaceutical Stocks
Deciphera Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.